# US 2016/0354367 A1 · Stem Cell Modulation II

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0354367 A1
- Document ID: US20160354367A1
- Status: Published application
- Kind: A1
- Application number: 15/023,358
- Filed: 2014-09-18
- Published: 2016-12-08
- Earliest claimed: 2013-09-18
- Assignees: University of Canberra
- Applicants: University of Canberra
- Inventors: Sudha RAO; Anjum ZAFAR
- Web page: https://patentgrep.com/patent/US20160354367A1

## CPC

- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 13/08: of the prostate
- A61P 13/10: of the bladder
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 17/00: Drugs for dermatological disorders
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- G01N 33/5758: {involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites}
- C12Q 2600/158: Expression markers
- G01N 2333/91205: Phosphotransferases in general
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Disclosed are methods and compositions for modulating cancer stem cells. More particularly, the present invention discloses the use of protein kinase C theta inhibitors (PKC-θ) for inhibiting the growth of PKC-θ-overexpressing cells including cancer stem cells, for enhancing the biological effects of chemotherapeutic drugs or irradiation on cancer cells, for treating cancer, including metastatic cancer and/or for preventing cancer recurrence.

## Claims

### Claim at position 1

-74. (canceled)

### Claim 75

A method for altering at least one of: (i) formation; (ii) proliferation; (iii) maintenance; (iv) epithelial to mesenchymal transition (EMT); or (v) mesenchymal to epithelial transition (MET) of a protein kinase C theta (PKC-θ)-overexpressing cell, the method comprising contacting the PKC-θ-overexpressing cell with a formation-, proliferation-, maintenance-; EMT- or MET-modulating amount of a PKC-θ inhibitor, wherein the PKC-θ-overexpressing cell is a cancer stem cell (CSC).

### Claim 76 (depends on 75)

A method according to claim 75, wherein the CSC is a breast CSC.

### Claim 77 (depends on 76)

A method according to claim 76, wherein the breast CSC is a breast epithelial CSC.

### Claim 78 (depends on 76)

A method according to claim 76, wherein the breast CSC is a breast ductal epithelial CSC.

### Claim 79 (depends on 75)

A method according to claim 75, wherein the CSC has impaired or abrogated expression of the pluripotent stem cell markers Oct4 or Sox2.

### Claim 80 (depends on 79)

A method according to claim 79, wherein the CSC expresses CD24 and CD44.

### Claim 81 (depends on 75)

A method according to claim 75, wherein the PKC-θ inhibitor is a selective PKC-θ inhibitor.

### Claim 82 (depends on 75)

A method according to claim 75, further comprising detecting overexpression of a PKC-θ gene in the PKC-θ-overexpressing cell prior to contacting the PKC-θ-overexpressing cell with the PKC-θ inhibitor.

### Claim 83 (depends on 75)

A method according to claim 75, further comprising detecting presence or an increased amount of PKC-θ in the nucleus of the PKC-θ-overexpressing cell prior to contacting the PKC-θ-overexpressing cell with the PKC-θ inhibitor.

### Claim 84 (depends on 75)

A method according to claim 75, further comprising detecting binding of PKC-θ to the promoter of CD44 or uPAR in the PKC-θ-overexpressing cell prior to contacting the PKC-θ-overexpressing cell with the PKC-θ inhibitor.

### Claim 85 (depends on 75)

A method according to claim 75, further comprising detecting binding of PKC-θ to chromatin in the PKC-θ-overexpressing cell prior to contacting the PKC-θ-overexpressing cell with the PKC-θ inhibitor.

### Claim 86 (depends on 75)

A method according to claim 75, further comprising detecting that the CSC has impaired or abrogated expression of the pluripotent stem cell markers Oct4 or Sox2.

### Claim 87

A method for treating or preventing a cancer in a subject, wherein the cancer comprises a cancer stem cell (CSC) and a non-CSC tumor cell, the method comprising administering to the subject a protein kinase C theta (PKC-θ) inhibitor in an effective amount to inhibit formation, proliferation, maintenance or epithelial to mesenchymal transition (EMT) of the CSC or to stimulate or induce mesenchymal to epithelial transition (MET) of the CSC.

### Claim 88 (depends on 87)

A method according to claim 87, wherein the cancer is a metastatic cancer.

### Claim 89 (depends on 87)

A method according to claim 87, further comprising identifying that the subject has or is at risk of developing a cancer comprising a CSC and a non-CSC tumor cell prior to the administration of the PKC-θ inhibitor.

### Claim 90 (depends on 87)

A method according to claim 87, wherein the cancer is breast cancer.

### Claim 91 (depends on 87)

A method according to claim 87, further comprising detecting overexpression of a PKC-θ gene in a tumor sample obtained from the subject, wherein the tumor sample comprises the CSC and/or the non-CSC tumor cell, prior to administering the PKC-θ inhibitor to the subject.

### Claim 92 (depends on 87)

A method according to claim 87, further comprising detecting that the CSC has impaired or abrogated expression of the pluripotent stem cell markers Oct4 or Sox2.

### Claim 93

A method for treating or preventing a cancer in a subject, wherein the cancer comprises a cancer stem cell (CSC) and a non-CSC tumor cell, the method comprising concurrently administering to the subject a protein kinase C theta (PKC-θ) inhibitor in an effective amount to inhibit formation, proliferation, maintenance or epithelial to mesenchymal transition (EMT) of the CSC or to stimulate or induce mesenchymal to epithelial transition (MET) of the CSC, and a cancer therapy or agent that inhibits the proliferation, survival or viability of the non-CSC tumor cell, to thereby treat or prevent the cancer.

### Claim 94 (depends on 93)

A method according to claim 93, wherein the cancer therapy or agent is selected from radiotherapy, surgery, chemotherapy, hormone ablation therapy, pro-apoptosis therapy and immunotherapy.

### Claim 95 (depends on 93)

A method according to claim 93, wherein the cancer therapy or agent targets rapidly dividing cells or disrupts the cell cycle or cell division.

### Claim 96 (depends on 93)

A method according to claim 93, wherein the cancer is a metastatic cancer.

### Claim 97 (depends on 93)

A method according to claim 93, wherein the cancer is breast cancer.

### Claim 98 (depends on 93)

A method according to claim 93, further comprising detecting overexpression of a PKC-θ gene in a tumor sample obtained from the subject, wherein the tumor sample comprises the CSC and/or the non-CSC tumor cell, prior to administering the PKC-θ inhibitor to the subject.

### Claim 99 (depends on 93)

A method according to claim 93, further comprising detecting that the CSC has impaired or abrogated expression of the pluripotent stem cell markers Oct4 or Sox2.
